Tags

Type your tag names separated by a space and hit enter

Postoperative radioactive iodine administration for differentiated thyroid cancer patients.

Abstract

PURPOSE OF REVIEW

Radioactive iodine (RAI) is administered postoperatively to the majority of thyroid cancer patients. No available study has demonstrated any benefit in low-risk patients.

RECENT FINDINGS

RAI should be used selectively in low and intermediate-risk patients, based on the surgical and pathological reports and on postoperative serum thyroglobulin level and neck ultrasonography. When used, a low activity (30 mCi) is administered following recombinant human thyrotropin stimulation. High-risk patients are treated with a high activity of RAI (100 mCi or more).

SUMMARY

RAI is not administered in many low-risk patients who can be reliably followed up with serum thyroglobulin determination on L-thyroxine treatment and neck ultrasonography. RAI may be administered in case of abnormality, and this delay will not reduce the chance of cure.

Authors+Show Affiliations

Gustave Roussy, University Paris Sud, Villejuif, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25119656

Citation

Lepoutre-Lussey, Charlotte, et al. "Postoperative Radioactive Iodine Administration for Differentiated Thyroid Cancer Patients." Current Opinion in Endocrinology, Diabetes, and Obesity, vol. 21, no. 5, 2014, pp. 363-71.
Lepoutre-Lussey C, Deandreis D, Leboulleux S, et al. Postoperative radioactive iodine administration for differentiated thyroid cancer patients. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):363-71.
Lepoutre-Lussey, C., Deandreis, D., Leboulleux, S., & Schlumberger, M. (2014). Postoperative radioactive iodine administration for differentiated thyroid cancer patients. Current Opinion in Endocrinology, Diabetes, and Obesity, 21(5), pp. 363-71. doi:10.1097/MED.0000000000000100.
Lepoutre-Lussey C, et al. Postoperative Radioactive Iodine Administration for Differentiated Thyroid Cancer Patients. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):363-71. PubMed PMID: 25119656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postoperative radioactive iodine administration for differentiated thyroid cancer patients. AU - Lepoutre-Lussey,Charlotte, AU - Deandreis,Désirée, AU - Leboulleux,Sophie, AU - Schlumberger,Martin, PY - 2014/8/15/entrez PY - 2014/8/15/pubmed PY - 2015/5/13/medline SP - 363 EP - 71 JF - Current opinion in endocrinology, diabetes, and obesity JO - Curr Opin Endocrinol Diabetes Obes VL - 21 IS - 5 N2 - PURPOSE OF REVIEW: Radioactive iodine (RAI) is administered postoperatively to the majority of thyroid cancer patients. No available study has demonstrated any benefit in low-risk patients. RECENT FINDINGS: RAI should be used selectively in low and intermediate-risk patients, based on the surgical and pathological reports and on postoperative serum thyroglobulin level and neck ultrasonography. When used, a low activity (30 mCi) is administered following recombinant human thyrotropin stimulation. High-risk patients are treated with a high activity of RAI (100 mCi or more). SUMMARY: RAI is not administered in many low-risk patients who can be reliably followed up with serum thyroglobulin determination on L-thyroxine treatment and neck ultrasonography. RAI may be administered in case of abnormality, and this delay will not reduce the chance of cure. SN - 1752-2978 UR - https://www.unboundmedicine.com/medline/citation/25119656/Postoperative_radioactive_iodine_administration_for_differentiated_thyroid_cancer_patients_ L2 - http://dx.doi.org/10.1097/MED.0000000000000100 DB - PRIME DP - Unbound Medicine ER -